Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers.
Target Price
The average target price of EVOK is 18 and suggests 64% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase